Pancreatic Cancer | Unmet Need | Locally advanced or metastatic adenocarcinoma | US/EU | 2017

Publish date: December 2017

Login to access report

Pancreatic cancer is a deadly disease with the majority of patients surviving less than one year. Despite huge advances in other oncology indications, treatment options for pancreatic cancer remain severely limited. Tarceva is currently the only approved targeted therapy for pancreatic cancer but offers limited survival benefits. The treatment landscape of pancreatic cancer is dominated by chemotherapeutic agents with limited efficacy advantages. This content presents a detailed analysis of pancreatic cancer treatment goals in locally advanced and metastatic settings. We assess how current therapies perform on key drug attributes and measure the impact of drug attributes on physicians’ prescribing behavior. We also consider which unmet needs novel therapies should address in order to distinguish themselves from their rivals and maximize uptake.

Questions Answered:

  • What are the treatment drivers and goals for pancreatic cancer?
  • What attributes are key influencers, which have limited impact, and which are hidden opportunities?
  • How do current therapies perform on key treatment drivers and goals for pancreatic cancer?
  • What are the prevailing areas of unmet need and opportunity in pancreatic cancer?
  • What trade-offs across different clinical attributes and price are acceptable to U.S. and European medical oncologists for a hypothetical new pancreatic cancer drug?

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 60 U.S. and 30 European medical oncologists fielded in March 2017.

Key companies: Celgene, Shire, Ipsen, Roche, Merck

Key drugs: Abraxane, Onivyde, Tarceva, Keytruda